ATE289294T1 - Pyrrolidin-derivate als faktor xa inhibitoren - Google Patents

Pyrrolidin-derivate als faktor xa inhibitoren

Info

Publication number
ATE289294T1
ATE289294T1 AT02738368T AT02738368T ATE289294T1 AT E289294 T1 ATE289294 T1 AT E289294T1 AT 02738368 T AT02738368 T AT 02738368T AT 02738368 T AT02738368 T AT 02738368T AT E289294 T1 ATE289294 T1 AT E289294T1
Authority
AT
Austria
Prior art keywords
inhibitors
factor
pyrrolidine derivatives
pyrrolidine
derivatives
Prior art date
Application number
AT02738368T
Other languages
English (en)
Inventor
Chuen Chan
Julie Nicole Hamblin
Henry Anderson Kelly
Nigel Paul King
Andrew Mcmurtrie Mason
Vipulkumar Kantibhai Patel
Stefan Senger
Gita Punjabhai Shah
Nigel Stephen Watson
Helen Elisabeth Weston
Caroline Whitworth
Robert John Young
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE289294T1 publication Critical patent/ATE289294T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT02738368T 2001-06-08 2002-06-06 Pyrrolidin-derivate als faktor xa inhibitoren ATE289294T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0114005.2A GB0114005D0 (en) 2001-06-08 2001-06-08 Chemical compounds
PCT/GB2002/002721 WO2002100830A1 (en) 2001-06-08 2002-06-06 Pyrrolidine derivatives as factor xa inhibitors

Publications (1)

Publication Number Publication Date
ATE289294T1 true ATE289294T1 (de) 2005-03-15

Family

ID=9916209

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02738368T ATE289294T1 (de) 2001-06-08 2002-06-06 Pyrrolidin-derivate als faktor xa inhibitoren

Country Status (28)

Country Link
US (4) US7186717B2 (de)
EP (1) EP1395553B1 (de)
JP (1) JP4242274B2 (de)
KR (1) KR100877245B1 (de)
CN (1) CN1256324C (de)
AR (1) AR036086A1 (de)
AT (1) ATE289294T1 (de)
AU (1) AU2002311451B2 (de)
BR (1) BR0210207A (de)
CA (1) CA2449629A1 (de)
CO (1) CO5540285A2 (de)
CZ (1) CZ20033325A3 (de)
DE (1) DE60203006T2 (de)
DK (1) DK1395553T3 (de)
ES (1) ES2235050T3 (de)
GB (1) GB0114005D0 (de)
HU (1) HUP0400156A3 (de)
IL (1) IL159195A0 (de)
MX (1) MXPA03011384A (de)
MY (1) MY136859A (de)
NO (1) NO326689B1 (de)
NZ (1) NZ530004A (de)
PL (1) PL368082A1 (de)
PT (1) PT1395553E (de)
SI (1) SI1395553T1 (de)
TW (1) TWI298719B (de)
WO (1) WO2002100830A1 (de)
ZA (1) ZA200309367B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
US20050119266A1 (en) * 2003-10-01 2005-06-02 Yan Shi Pyrrolidine and piperidine derivatives as factor Xa inhibitors
ATE533491T1 (de) 2004-09-21 2011-12-15 Trobio Ab Stabilisierte protease zusammensetzungen enthaltend eine serinprotease, morpholin-derivate und reversible serinprotease- inhibitoren
US7446210B2 (en) * 2004-10-26 2008-11-04 Janssen Pharmaceutica N.V. Factor Xa compounds
WO2006110726A2 (en) * 2005-04-11 2006-10-19 Glaxo Group Limited Dosage formulations and methods of treatment and prevention
CN102380100A (zh) * 2005-09-22 2012-03-21 特罗比奥股份公司 稳定的蛋白酶组合物
CA2621059C (en) * 2005-09-22 2013-08-13 Trobio Ab Stabilized protease composition
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
WO2014174102A1 (en) * 2013-04-26 2014-10-30 Sanofi Tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(s)-2-[methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl piperazin-1 -yl)-3-oxo-propryl]amide
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP3078378B1 (de) 2015-04-08 2020-06-24 Vaiomer Verwendung von faktor-xa-inhibitoren zur regulierung von glykämie
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4121947A1 (de) 1991-07-03 1993-01-07 Basf Ag 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung
US5703208A (en) 1994-06-17 1997-12-30 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
WO1998016523A2 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
US6602864B1 (en) 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
US6281227B1 (en) 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
DE69715658T2 (de) 1996-12-13 2003-05-22 Aventis Pharmaceuticals Inc., Collegeville Sulfonsäure oder sulfonylamino n-(heteroaralkyl)-azaheterocyclylamid verbindungen
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
WO1999016747A1 (en) * 1997-09-30 1999-04-08 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
YU47600A (sh) 1998-01-27 2002-09-19 Aventis Pharmaceuticals Products Inc. SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
US6281277B1 (en) 1998-04-22 2001-08-28 Showa Denko Kabushiki Kaisha Homogeneously surface-fluorinated metal oxide particulates, process for manufacturing the same, and use of the same
CA2358939A1 (en) 1998-12-31 2000-07-13 Joseph P. Burkhart 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
WO2000047563A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Co. LACTAM INHIBITORS OF FXa AND METHOD
AU3192500A (en) 1999-03-16 2000-10-04 C & C Research Laboratories Substituted proline derivatives and medicinal compositions containing the same
WO2000069465A1 (en) 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Anticancer agents containing ep1 antagonists as the active ingredient
KR20020087041A (ko) 1999-07-28 2002-11-21 아벤티스 파마슈티칼스 프로덕츠 인크. 치환된 옥소아자헤테로사이클릴 화합물
HUP0304058A2 (hu) 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
US20070155745A1 (en) 2007-07-05
US20050107379A1 (en) 2005-05-19
CN1256324C (zh) 2006-05-17
HUP0400156A2 (hu) 2004-07-28
DE60203006D1 (de) 2005-03-24
CA2449629A1 (en) 2002-12-19
ZA200309367B (en) 2004-08-02
NZ530004A (en) 2005-08-26
PT1395553E (pt) 2005-06-30
CO5540285A2 (es) 2005-07-29
NO20035440D0 (no) 2003-12-05
TWI298719B (en) 2008-07-11
US7326785B2 (en) 2008-02-05
EP1395553B1 (de) 2005-02-16
AR036086A1 (es) 2004-08-11
MXPA03011384A (es) 2004-04-05
HUP0400156A3 (en) 2008-10-28
DK1395553T3 (da) 2005-06-06
KR100877245B1 (ko) 2009-01-07
IL159195A0 (en) 2004-06-01
PL368082A1 (en) 2005-03-21
WO2002100830A1 (en) 2002-12-19
JP4242274B2 (ja) 2009-03-25
US7429587B2 (en) 2008-09-30
CZ20033325A3 (cs) 2004-08-18
US20070142375A1 (en) 2007-06-21
BR0210207A (pt) 2004-08-03
ES2235050T3 (es) 2005-07-01
JP2004537530A (ja) 2004-12-16
NO326689B1 (no) 2009-01-26
GB0114005D0 (en) 2001-08-01
SI1395553T1 (en) 2005-06-30
CN1538955A (zh) 2004-10-20
HK1063471A1 (en) 2004-12-31
AU2002311451B2 (en) 2006-03-02
US7517879B2 (en) 2009-04-14
MY136859A (en) 2008-11-28
US7186717B2 (en) 2007-03-06
KR20040004706A (ko) 2004-01-13
EP1395553A1 (de) 2004-03-10
DE60203006T2 (de) 2006-03-30
US20070142374A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
NO20042592L (no) Indol-2-karboksamider som faktor XA inhibitorer
NO20021230D0 (no) Inhibitorer for faktor Xa
NO20041163L (no) Laktam-inneholdende forbindelser og derivater derav som faktor XA-inhibitorer
ATE444292T1 (de) Pyrazolderivate als faktor-xa-inhibitoren
AU2002350217A8 (en) Glycinamides as factor xa inhibitors
EP1684744A4 (de) Pyrrolidin- und piperidin-derivate als faktor-xa-hemmer
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
DE60329282D1 (de) Cyano-pyrrolidine als DPP-IV Inhibitoren
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
DE60123294D1 (de) Diazepan Derivate als Faktor X Inhibitor
DE60203006D1 (de) Pyrrolidin-derivate als faktor xa inhibitoren
AU2002365896A8 (en) Substituted amino methyl factor xa inhibitors
DE60008524D1 (de) Furanonderivate als inhibitoren von cathepsin s
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren
ATE330940T1 (de) Pyrrolidin-derivate verwendbar als bax- inhibitoren
NO20042990L (no) Pyrrolidin-2-oner som faktor XA inhibitorer
NO20014234D0 (no) Pyrazol-3-on-derivater som faktor-Xa-inhibitorer
ATE401322T1 (de) Imidazolderivate als faktor-xa-inhibitoren
ATE305452T1 (de) Faktor xa inhibitor
ATE474838T1 (de) Benzimidazolderivate als faktor xa-inhibitoren
DE502004012284D1 (de) Carbonsäureamidderivate und ihre verwendung als faktor xa inhibitoren
DE502004011365D1 (de) Ethynylderivate als faktor xa-inhibitoren
HK1069393A (en) Pyrrolidine-2-ones as factor xa inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1395553

Country of ref document: EP

REN Ceased due to non-payment of the annual fee